Little Green Pharma (ASX:LGP) receives manufacturing permit

Insights

11 May 2020

Approved stamp image
Little Green Pharma has been granted a new manufacturing permit from the office of drug control

Medicinal cannabis company, Little Green Pharma (LGP) has been granted a new manufacturing permit from the office of drug control.

The manufacturing permit will allow the company to manufacture cannabis extracts for holders of therapeutic goods administration (TGA) GMP manufacturing licences to produce medicinal cannabis products.

Little Green has an exclusive agreement with its GMP-licenced manufacturing partner to produce the products.

The permit is valid for one year and ends in March 2021. This new permit will also allow the company to commence in-house extraction once the next crop is harvested, which is set to reduce costs and improve efficiencies.

Managing Director Fleta Solomon said receiving this permit also gives the company the capability to manufacture cannabis extracts at its manufacturing premises.

"We are now only waiting for our expanded ODC Medicinal Cannabis Cultivation and Production Permit which, once granted, will allow us to begin first planting at our expanded cultivation facility and to significantly expand our production operations," she said.

Read the full article by Lisa Simcock, Markets Reporter here: https://themarketherald.com.au/little-green-pharma-asxlgp-receives-manufacturing-permit-2020-05-11/

You might also be interested in

UK flag

Insights

UK patients to access first-ever export of Australian medicinal cannabis oil

An Australian first. Read more on our export of medicinal cannabis for UK patients.

Apr 2020

Fleta Solomon MD green polo

Insights

Big plans for Little Green Pharma

Read more on the Australian firm hoping to help more UK patients benefit from medical cannabis.

Apr 2020

Doctor hand holding cannabis and pills

Insights

Is Cannabis the Solution to the Chronic Pain Crisis?

A new study has found that medicinal cannabis may be able to reduce the intensity of chronic pain in patients by as much as 30%.

Dec 2019

View all articles